Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded
Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year t
Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe
With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.<
Bristol-Myers Squibb has decided it wants complete, worldwide control of cardiovascular drug mavacamten, tipped as a future blockbuster, so it has paid $350 million to sho
Five months after Sanofi backed away from a proposed deal with Maze Therapeutics on a Pompe disease therapy after an antitrust challenge, Shionogi has snapped up the drug.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.